Physician profile
Spencer Weston
NPI 1326487794
$2,506.52
in general payments reported to CMS, 2019-2025
23 companies · $548 in 2025
The $548 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $215 · 2021: $430 · 2022: $353 · 2023: $413 · 2024: $395 · 2025: $548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,303 · Education: $53.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,303.21 |
| Education | $53.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $647.23 | 2019-2025 | Vraylar |
| Astrazeneca Pharmaceuticals Lp | $339.46 | 2025 | Airsupra, Breztri |
| Teva Pharmaceuticals USA, INC. | $332.90 | 2019-2024 | Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $133.50 | 2022-2024 | Spravato, Invega Sustenna |
| Novo Nordisk INC | $120.65 | 2021-2025 | Ozempic |
| Lilly USA, LLC | $116.24 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $111.05 | 2022-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Pfizer INC. | $100.99 | 2020-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.96 | 2021-2024 | Caplyta |
| Sunovion Pharmaceuticals INC. | $70.79 | 2022 | |
| Allergan, INC. | $62.92 | 2019-2020 | |
| Medtronic, INC. | $54.17 | 2021 | |
| Glaxosmithkline, LLC. | $51.91 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $50.71 | 2022-2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $44.94 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $39.02 | 2022 | |
| Alkermes, INC. | $33.57 | 2023-2024 | Lybalvi |
| Supernus Pharmaceuticals, INC. | $23.50 | 2021 | |
| Amgen INC. | $22.32 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.75 | 2023 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.94 | 2019 | |
| Kerr Corporation | $17.02 | 2019 | |
| Boston Scientific Corporation | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spencer Weston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.